YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Investing.com -- Raymond James has identified its top stock picks in the healthcare sector, highlighting companies with upcoming clinical trial results and promising drug development programs. The firm's Analyst Current Favorites list feat…
Dyne Therapeutics, Inc. WALTHAM, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular…
The S&P 500 Index ($SPX) (SPY) closed down -0.48% on Wednesday, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -0.77%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.29%. E-mini S&P futures (ESU26) fell -0.46%, and Septe…
The S&P 500 Index ($SPX) (SPY) is down -0.25% today, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.69%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.12%. E-mini S&P futures (ESU26) are down -0.92%, and September E-mini Nasda…
Dyne Therapeutics (DYN) investment thesis remains intact despite a setback for Novartis (NVS) in a p PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
The S&P 500 Index ($SPX) (SPY) is down -0.25% today, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.69%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.12%. E-mini S&P futures (ESU26) are down -0.92%, and September E-mini Nasda…
Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compile…
The S&P 500 Index ($SPX) (SPY) closed down -0.58% on Tuesday, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.18%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.12%. E-mini S&P futures (ESU26) fell -0.57%, and Septemb…
The S&P 500 Index ($SPX) (SPY) is down -0.32% today, the Dow Jones Industrial Average ($DOWI) (DIA) is down -1.04%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.04%. E-mini S&P futures (ESU26) are down -0.33%, and September E-mini Nas…
Following two trial misses and a third clinical setback, analysts fear Novartis may miss its 2030 growth targets without further acquisitions. Continue Reading
The S&P 500 Index ($SPX) (SPY) is down -0.34% today, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.83%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.19%. E-mini S&P futures (ESU26) are down -0.41%, and September E-mini Nas…
Bad news from Swiss pharmaceutical giant Novartis was weighing on the Dow on Tuesday. - Fabrice Coffrini/Agence France-Presse/Getty Images Investors returning from the Labor Day break could be forgiven for wondering if their eyes were dece…
Medical research blood test vial ©PXHere Dyne Therapeutics (NASDAQ:DYN) shares fell 31.0% to $16.76 in premarket trading, compared with a previous close of $24.28. No official company announcement confirming a reason for the share-price mo…
[Scientist use ai technology, biotechnology for Medical research and development of scientific lab. Medical Research Laboratory for Test and analysis chromosome DNA genetic.] Swiss drugmaker Novartis' (NVS [https://seekingalpha.com/symbol/…
(RTTNews) - The following biotech stocks reached a 52-week high on August 11, 2026, driven up by key catalysts such as positive quarterly or full year reports. Alamar Biosciences Inc. (ALMR) Alamar Biosciences is a proteomics company that…
* Dyne Therapeutics press release [https://seekingalpha.com/pr/20600342-dyne-therapeutics-reports-second-quarter-2026-financial-results-and-recent-business] (DYN [https://seekingalpha.com/symbol/DYN]): Q2 GAAP EPS of -$1.08 misses by $0.33…
- Company’sthird program to enter clinical development leveraging FORCE platform with the goal of delivering functional improvement in rare neuromuscular disease - WALTHAM, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (…
WALTHAM, Mass., July 24, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announce…
Dyne Therapeutics, Inc. WALTHAM, Mass., July 24, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular…
Shares of Sarepta Therapeutics SRPT fell nearly 10% over the past week. This decline likely reflects growing investor concerns about the company's position in the Duchenne muscular dystrophy (DMD) landscape following a key regulatory miles…
Medical research testing ©rawpixel Discounted share sale weighs on stock Dyne Therapeutics, Inc. (NASDAQ:DYN) shares fell 9% on Wednesday after the biotechnology company priced a public offering of common stock expected to raise approximat…
Dyne Therapeutics (DYN [https://seekingalpha.com/symbol/DYN]) has announced the pricing of an upsized [https://seekingalpha.com/pr/20590706-dyne-therapeutics-announces-pricing-of-upsized-375-million-public-offering-of-common-stock] underwr…
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announce…
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announce…
Dyne Therapeutics' DYN shares have gained 19.2% over the past three months, driven by increasing investor confidence in its late-stage neuromuscular disease pipeline. Optimism has been fueled by positive regulatory progress for its lead Du…
Sarepta stock took a hit after Dyne Therapeutics said the FDA would review its exon 51-skipping drug in Duchenne patients. Continue Reading
Dyne Therapeutics stock briefly jumped Monday after the FDA agreed to review the company's muscular dystrophy drug. Continue Reading
- Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion cohort of the DELIVER trial, treatment wit…
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 affordable biotech stocks to buy right now. On June 26, TD Cowen initiated its coverage of Dyne Therapeutics Inc. (NASDAQ:DYN), assigning a Buy rating to the stock. The firm stated that…
Choosing between Dyne Therapeutics (NASDAQ:DYN) and Recursion Pharmaceuticals (NASDAQ:RXRX) requires balancing the potential of targeted muscle-tissue therapies against the broad, data-driven power of artificial intelligence in drug discov…
Choosing between a high-growth clinical-stage player and an established industry titan can be difficult for investors. This comparison examines Dyne Therapeutics (NASDAQ:DYN) and Vertex Pharmaceuticals (NASDAQ:VRTX) to help you determine t…
Devon Energy Corporation (NYSE:DVN) is one of the best value stocks to buy right now. On June 24, Devon Energy Corporation announced the final results of its private exchange offers to swap outstanding notes issued by its subsidiary, Coter…
Key Points Dyne Therapeutics is leveraging its FORCE platform to target rare neuromuscular diseases with high unmet need. Viking Therapeutics is focused on the massive weight-loss and metabolic market with its clinical-stage candidates. Wh…
High-stakes clinical trials define the 2026 landscape for Dyne Therapeutics (NASDAQ:DYN) and Viking Therapeutics (NASDAQ:VKTX). Both firms seek to revolutionize patient care while navigating the complex path toward regulatory approval. Dyn…
(RTTNews) - Dyne Therapeutics, Inc. (DYN), a clinical-stage company, announced the appointment of Barry Greene to its Board of Directors. Greene brings more than 30 years of experience in the biopharmaceutical industry, with expertise in t…
WALTHAM, Mass., June 18, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announce…